Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SNSE
$35.07
$
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Beta
0.279
Average Volume
Market Cap
Last Dividend
CIK
0001829802
ISIN
US81728A2078
CUSIP
81728A207
CEO
Christopher W. Gerry
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
14
IPO Date
2021-02-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Sensei Biotherapeutics Stock Soars 230% After Faeth Deal | SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer. | Benzinga | 2026-02-18 12:09:43 |
| Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement | BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth's lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into. | Business Wire | 2026-02-18 08:00:00 |
| Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis | Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends. Analyst Recommendations This is a summary of | Defense World | 2026-01-14 02:16:54 |
| Egle Therapeutics Appoints John Celebi as Chief Executive Officer | PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today announced the appointment of John Celebi, M.B.A., as chief executive officer. Mr. Celebi is a seasoned biotechnology executive with over 30 years of experience building and scaling innovative life sciences companies and has been a member of the Egle board of directors since 2024. | GlobeNewsWire | 2026-01-07 08:00:00 |
| What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump? | Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing shareholder activity drawing attention. | Benzinga | 2025-12-05 01:31:52 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 3 | 2026-02-19 | 2026-02-19 | View Filing |
| 8-K | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-17 | 2026-02-17 | View Filing |
| 3 | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-13 | 2026-02-13 | View Filing |
| 8-K | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 3 | 2025-11-24 | 2025-11-24 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-07-09 | 2025-07-09 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| 10-Q | 2025-05-06 | 2025-05-06 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| ARS | 2025-04-11 | 2025-04-11 | View Filing |
| DEFA14A | 2025-04-11 | 2025-04-11 | View Filing |
| DEF 14A | 2025-04-11 | 2025-04-11 | View Filing |
| PRE 14A | 2025-04-01 | 2025-04-01 | View Filing |
| S-8 | 2025-03-28 | 2025-03-28 | View Filing |
| 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-10-30 | 2024-10-30 | View Filing |
| 3 | 2024-09-26 | 2024-09-26 | View Filing |
| 8-K | 2024-09-20 | 2024-09-20 | View Filing |
| 10-Q | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-07-12 | 2024-07-12 | View Filing |
| 8-K | 2024-06-27 | 2024-06-27 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 8-K | 2024-06-13 | 2024-06-13 | View Filing |
| 8-K | 2024-06-03 | 2024-06-03 | View Filing |
| 8-K | 2024-05-23 | 2024-05-23 | View Filing |
| 3 | 2024-05-16 | 2024-05-16 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 8-K | 2024-04-12 | 2024-04-12 | View Filing |
| 8-K | 2024-04-02 | 2024-04-02 | View Filing |
| SC 13D/A | 2024-03-07 | 2024-03-07 | View Filing |
| 8-K | 2024-03-05 | 2024-03-05 | View Filing |
| S-8 | 2024-02-29 | 2024-02-29 | View Filing |
| 10-K | 2024-02-29 | 2024-02-29 | View Filing |
| 8-K | 2024-02-28 | 2024-02-28 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| VWAP | 22.67% | 0.98 | 39 | 0.41 | 0.27 | 38.92 |
| Adaptive Wave | 22.48% | 2 | 3 | 0.76 | 0.87 | 12.63 |
| Bull Bias | 19.65% | 0.99 | 39 | 0.61 | 1.81 | 9.79 |
| xxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxx% | xxxx | xx | xx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |